The possibility of targeting LIF as a method of combatting chemoresistance has been studied extensively in pancreatic cancer, where genetic and pharmacologic inhibition of LIF signaling has been seen to improve chemotherapy efficacy in studies of cell lines and in mouse models [17,108]. This evidence concerns the gene LIF and pancreatic neoplasm.